Literature DB >> 18463637

Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation.

Wei Guo1, Joseph L Lasky, Chun-Ju Chang, Sherly Mosessian, Xiaoman Lewis, Yun Xiao, Jennifer E Yeh, James Y Chen, M Luisa Iruela-Arispe, Marileila Varella-Garcia, Hong Wu.   

Abstract

Cancer stem cells, which share many common properties and regulatory machineries with normal stem cells, have recently been proposed to be responsible for tumorigenesis and to contribute to cancer resistance. The main challenges in cancer biology are to identify cancer stem cells and to define the molecular events required for transforming normal cells to cancer stem cells. Here we show that Pten deletion in mouse haematopoietic stem cells leads to a myeloproliferative disorder, followed by acute T-lymphoblastic leukaemia (T-ALL). Self-renewable leukaemia stem cells (LSCs) are enriched in the c-Kit(mid)CD3(+)Lin(-) compartment, where unphosphorylated beta-catenin is significantly increased. Conditional ablation of one allele of the beta-catenin gene substantially decreases the incidence and delays the occurrence of T-ALL caused by Pten loss, indicating that activation of the beta-catenin pathway may contribute to the formation or expansion of the LSC population. Moreover, a recurring chromosomal translocation, T(14;15), results in aberrant overexpression of the c-myc oncogene in c-Kit(mid)CD3(+)Lin(-) LSCs and CD3(+) leukaemic blasts, recapitulating a subset of human T-ALL. No alterations in Notch1 signalling are detected in this model, suggesting that Pten inactivation and c-myc overexpression may substitute functionally for Notch1 abnormalities, leading to T-ALL development. Our study indicates that multiple genetic or molecular alterations contribute cooperatively to LSC transformation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18463637      PMCID: PMC2840044          DOI: 10.1038/nature06933

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  27 in total

1.  Detection of E2A translocations in leukemias via fluorescence in situ hybridization.

Authors:  T Boomer; M Varella-Garcia; L McGavran; L Meltesen; A S Olsen; S P Hunger
Journal:  Leukemia       Date:  2001-01       Impact factor: 11.528

2.  Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene.

Authors:  Ralf Lesche; Matthias Groszer; Jing Gao; Ying Wang; Albee Messing; Hong Sun; Xin Liu; Hong Wu
Journal:  Genesis       Date:  2002-02       Impact factor: 2.487

3.  A role for Wnt signalling in self-renewal of haematopoietic stem cells.

Authors:  Tannishtha Reya; Andrew W Duncan; Laurie Ailles; Jos Domen; David C Scherer; Karl Willert; Lindsay Hintz; Roel Nusse; Irving L Weissman
Journal:  Nature       Date:  2003-04-27       Impact factor: 49.962

4.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

Authors:  Catriona H M Jamieson; Laurie E Ailles; Scott J Dylla; Manja Muijtjens; Carol Jones; James L Zehnder; Jason Gotlib; Kevin Li; Markus G Manz; Armand Keating; Charles L Sawyers; Irving L Weissman
Journal:  N Engl J Med       Date:  2004-08-12       Impact factor: 91.245

5.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

Review 6.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

7.  JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells.

Authors:  Emmanuelle Passegué; Erwin F Wagner; Irving L Weissman
Journal:  Cell       Date:  2004-10-29       Impact factor: 41.582

Review 8.  Translocations involving c-myc and c-myc function.

Authors:  L M Boxer; C V Dang
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

9.  Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.

Authors:  Teresa Palomero; Maria Luisa Sulis; Maria Cortina; Pedro J Real; Kelly Barnes; Maria Ciofani; Esther Caparros; Jean Buteau; Kristy Brown; Sherrie L Perkins; Govind Bhagat; Archana M Agarwal; Giuseppe Basso; Mireia Castillo; Satoru Nagase; Carlos Cordon-Cardo; Ramon Parsons; Juan Carlos Zúñiga-Pflücker; Maria Dominguez; Adolfo A Ferrando
Journal:  Nat Med       Date:  2007-09-16       Impact factor: 53.440

10.  Deregulation of c-myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias.

Authors:  J Erikson; L Finger; L Sun; A ar-Rushdi; K Nishikura; J Minowada; J Finan; B S Emanuel; P C Nowell; C M Croce
Journal:  Science       Date:  1986-05-16       Impact factor: 47.728

View more
  121 in total

1.  Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling.

Authors:  Shiuan Wey; Biquan Luo; Chun-Chih Tseng; Min Ni; Hui Zhou; Yong Fu; Deepa Bhojwani; William L Carroll; Amy S Lee
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

2.  PTEN regulates PLK1 and controls chromosomal stability during cell division.

Authors:  Zhong Zhang; Sheng-Qi Hou; Jinxue He; Tingting Gu; Yuxin Yin; Wen H Shen
Journal:  Cell Cycle       Date:  2016-07-11       Impact factor: 4.534

3.  Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus.

Authors:  Yan Liu; Fan Liu; Hao Yu; Xinyang Zhao; Goro Sashida; Anthony Deblasio; Michael Harr; Qing-Bai She; Zhenbang Chen; Hui-Kuan Lin; Silvana Di Giandomenico; Shannon E Elf; Youyang Yang; Yasuhiko Miyata; Gang Huang; Silvia Menendez; Ingo K Mellinghoff; Neal Rosen; Pier Paolo Pandolfi; Cyrus V Hedvat; Stephen D Nimer
Journal:  Sci Signal       Date:  2012-10-23       Impact factor: 8.192

4.  Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.

Authors:  Hind Medyouf; Xiuhua Gao; Florence Armstrong; Samuel Gusscott; Qing Liu; Amanda Larson Gedman; Larry H Matherly; Kirk R Schultz; Francoise Pflumio; Mingjian James You; Andrew P Weng
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

5.  L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia.

Authors:  C Rosilio; M Nebout; V Imbert; E Griessinger; Z Neffati; J Benadiba; T Hagenbeek; H Spits; J Reverso; D Ambrosetti; J-F Michiels; B Bailly-Maitre; H Endou; M F Wempe; J-F Peyron
Journal:  Leukemia       Date:  2014-12-08       Impact factor: 11.528

6.  Zebrafish as a model for cancer self-renewal.

Authors:  Myron S Ignatius; David M Langenau
Journal:  Zebrafish       Date:  2009-12       Impact factor: 1.985

7.  Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.

Authors:  Eleonora Sementino; Craig W Menges; Yuwaraj Kadariya; Suraj Peri; Jinfei Xu; Zemin Liu; Richard G Wilkes; Kathy Q Cai; Frank J Rauscher; Andres J Klein-Szanto; Joseph R Testa
Journal:  J Cell Physiol       Date:  2018-06-15       Impact factor: 6.384

Review 8.  Crosstalk of Notch with p53 and p63 in cancer growth control.

Authors:  G Paolo Dotto
Journal:  Nat Rev Cancer       Date:  2009-07-16       Impact factor: 60.716

Review 9.  Building a framework for embryonic microenvironments and cancer stem cells.

Authors:  Antonio Ruiz-Vela; Cristóbal Aguilar-Gallardo; Carlos Simón
Journal:  Stem Cell Rev Rep       Date:  2009-12       Impact factor: 5.739

10.  High-throughput cell transplantation establishes that tumor-initiating cells are abundant in zebrafish T-cell acute lymphoblastic leukemia.

Authors:  Alexandra C H Smith; Aubrey R Raimondi; Chris D Salthouse; Myron S Ignatius; Jessica S Blackburn; Igor V Mizgirev; Narie Y Storer; Jill L O de Jong; Aye T Chen; Yi Zhou; Sergei Revskoy; Leonard I Zon; David M Langenau
Journal:  Blood       Date:  2010-01-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.